BioCentury | Dec 4, 2020

Dec. 3 Quick Takes: Israeli digital health firm closes $170M fund; plus BioAge, newco Rubedo, Portal Innovations, OliX

OTV closes $170M fundIsrael-based digital health VC OTV has changed its name from Olive Tree Ventures and closed a $170 million fund. The firm also said it hired Jose Antonio Urrutia Rivas, who was an associate...
BioCentury | Oct 3, 2020
Management Tracks

Li to guide Merck’s next wave of cancer therapies launched by Perlmutter

Dean Li will take over a Merck Research Laboratories that has been transformed by Roger Perlmutter over the past seven years, guiding a pharma that had been struggling with a patent cliff to the company...
BioCentury | Sep 26, 2020
Product Development

Merck’s myeloid data add support for the emerging target class

The myeloid cell targets that have been generating preclinical attention are moving into the clinical arena, and the first look at data from Merck’s ILT4 program provides an early signal that the strategy...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

Incyte moving into Phase III with PD-1 inhibitor retifanlimab for SCACIncyte Corp. (NASDAQ:INCY) reported its PD-1 inhibitor retifanlimab led to an objective response rate of 14% and a disease control rate of 49% in the...
BioCentury | Sep 4, 2020
Product Development

Akebia’s prospects dim after safety readout in non-dialysis CKD patients

The failure of Akebia’s vadadustat on a Phase III safety endpoint in a subset of chronic kidney disease patients won’t stop the company from submitting the molecule to regulators. But the readout surprised...
BioCentury | Jul 21, 2020
Product Development

Data Bytes: COVID-19 pipeline still growing

Last week saw at least 17 new programs added to the COVID-19 pipeline, bringing the total number of candidates BioCentury is tracking in its COVID-19 Resource Center to 679. Among the 12 new therapeutic entrants...
BioCentury | Jun 30, 2020

Data Bytes: Drug approvals in Japan

On Monday, Japan’s Ministry of Health, Labour and Welfare announced at least nine drug approvals, five of which are products from Novartis AG (NYSE:NVS; SIX:NOVN). Two of the approvals are for HIF-PH inhibitors to treat...
BioCentury | May 28, 2020
Distillery Therapeutics

Reducing kidney damage in lupus by targeting HIF1A

...include mechanistic studies of HIF1A blockade as therapeutic strategy for lupus. TARGET/MARKER/PATHWAY: Hypoxia-inducible factor 1 α (HIF1A; HIF1-α...
...Yale School of Medicine, New Haven, Conn. email: Claire Quang Yale School of Medicine Hypoxia-inducible factor 1 alpha (HIF1A) (HIF1-alpha...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

TG’s combo meets Phase III leukemia endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib met the primary endpoint of progression-free survival (PFS) in...
BioCentury | Feb 6, 2020

Beyond Keytruda: How Merck envisions innovation and growth after a spinout

As Merck becomes the latest large pharma to split in two, separating its key growth drivers and innovative programs from its slower-growing businesses, the slimmed-down innovative company will rely on the fruits of recent and...
Items per page:
1 - 10 of 376